Figure 3 - available via license: CC BY-NC-ND
Content may be subject to copyright.
Histopathological examination revealed nodular hyperplasia of thyroid gland and atypical parathyroid adenomas of four glands. Nodular structures were seperated by fibrous septae. No typical findings suggestive of parathyroid carcinoma like mitosis, atypia or vascular invasion were observed (hematoxylin and eosin, magnification x400). Preoperatively, serum parathormone (PTH) was 1876 pg/mL, Ca was 10.14 mg/dL and P was 5.02 mg/dL. Following the operation, serum PTH level dropped to 99 pg/mL and serum Ca level was 9.7 mg/dL. Tertiary hyperparathyroidism is mostly caused by hyperplasia and rarely by adenoma (1). Atypical parathyroid adenoma is a rare entity with borderline pathological characteristics, between adenoma and carcinoma (2). Parathyroid surgery is a relatively hard procedure as it necessitates surgical skill and experience. The use of Tc-99m MIBI scintigraphy is well established for patients undergoing reoperation for hyperparathyroidism. Some surgeons tend to skip preoperative imaging in secondary or tertiary hyperparathyroidism because bilateral neck exploration is needed anyway, but some studies suggested that parathyroid scintigraphy could be of value before initial parathyroidectomy (3,4). Tc-99m MIBI scintigraphy may help recognize an unexpected appearance of an ectopic or supernumerary parathyroid gland, as well as show the gland with the least radiotracer accumulation that can be autotransplanted. Protocol of parathyroid scan is argued to be important. Although dual isotope techniques are reported to be superior to dual phase imaging and SPECT/CT is recommended strongly to provide topographic anatomic information, in this case, both four pathological glands could still be identified by dual phase Tc-99m MIBI SPECT (5). Ultrasonography (USG) and Tc-99m MIBI scintigraphy are complementary in parathyroid imaging. The success of both modalities is similar in single gland disease. However, in case of multiglandular disease, frequently seen in secondary or tertiary hyperparathyroidism, they have been reported to have lower sensitivities. Thus, especially in these patients, combination of scintigraphic and sonographic imaging provides a more accurate approach in the preoperative evaluation (6). In our case, MIBI was capable of detecting atypical adenomas in four parathyroid glands with respect to one gland demonstrated by USG. This report is interesting in the way that atypical adenomas of parathyroid gland were presented in all four of the glands in a patient with tertiary hyperparathyroidism and that the only preoperative method that could address multiglandular disease was Tc-99m MIBI SPECT.

Histopathological examination revealed nodular hyperplasia of thyroid gland and atypical parathyroid adenomas of four glands. Nodular structures were seperated by fibrous septae. No typical findings suggestive of parathyroid carcinoma like mitosis, atypia or vascular invasion were observed (hematoxylin and eosin, magnification x400). Preoperatively, serum parathormone (PTH) was 1876 pg/mL, Ca was 10.14 mg/dL and P was 5.02 mg/dL. Following the operation, serum PTH level dropped to 99 pg/mL and serum Ca level was 9.7 mg/dL. Tertiary hyperparathyroidism is mostly caused by hyperplasia and rarely by adenoma (1). Atypical parathyroid adenoma is a rare entity with borderline pathological characteristics, between adenoma and carcinoma (2). Parathyroid surgery is a relatively hard procedure as it necessitates surgical skill and experience. The use of Tc-99m MIBI scintigraphy is well established for patients undergoing reoperation for hyperparathyroidism. Some surgeons tend to skip preoperative imaging in secondary or tertiary hyperparathyroidism because bilateral neck exploration is needed anyway, but some studies suggested that parathyroid scintigraphy could be of value before initial parathyroidectomy (3,4). Tc-99m MIBI scintigraphy may help recognize an unexpected appearance of an ectopic or supernumerary parathyroid gland, as well as show the gland with the least radiotracer accumulation that can be autotransplanted. Protocol of parathyroid scan is argued to be important. Although dual isotope techniques are reported to be superior to dual phase imaging and SPECT/CT is recommended strongly to provide topographic anatomic information, in this case, both four pathological glands could still be identified by dual phase Tc-99m MIBI SPECT (5). Ultrasonography (USG) and Tc-99m MIBI scintigraphy are complementary in parathyroid imaging. The success of both modalities is similar in single gland disease. However, in case of multiglandular disease, frequently seen in secondary or tertiary hyperparathyroidism, they have been reported to have lower sensitivities. Thus, especially in these patients, combination of scintigraphic and sonographic imaging provides a more accurate approach in the preoperative evaluation (6). In our case, MIBI was capable of detecting atypical adenomas in four parathyroid glands with respect to one gland demonstrated by USG. This report is interesting in the way that atypical adenomas of parathyroid gland were presented in all four of the glands in a patient with tertiary hyperparathyroidism and that the only preoperative method that could address multiglandular disease was Tc-99m MIBI SPECT.

Source publication
Article
Full-text available
We report a case of a 55-year-old female with tertiary hyperparathyroidism and osteoporosis who had end stage renal disease and a history of hemodialysis for 15 years. Patient’s informed is taken. Neck ultrasonography showed multinodular goiter together with a hypoechoic lesion compatible with a parathyroid adenoma. Dual phase technetium (Tc) Tc-99...

Citations

... In addition, 99m Tc has unique coordination chemistry, which allows conjugation with a broad spectrum of diverse pharmaceutical molecules (IAEA, 2009;Dilworth and Pascu, 2015;Boschi et al., 2017;Gumiela, 2018). These 99m Tc-labelled compounds have been involved in the visualization of most organs (Vallabhajosula et al., 1989;Zolle, 2007;Leggett and Giussani, 2015;Araz et al., 2020;Urbano et al., 2020;Parihar et al., 2021). Moreover, the global on-demand availability of 99m Tc through the user-friendly 99 Mo/ 99m Tc generators with reasonable cost-effectiveness has 99 Mo → 99m Tc ( 99 Mo/ 99m Tc generator) 100 Mo(p,2n) 99m Tc 100 Mo(d,3n) The data were deduced from: a https://www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html ...
Article
Full-text available
The continuing rapid expansion of 99mTc diagnostic agents always calls for scaling up 99mTc production to cover increasing clinical demand. Nevertheless, 99mTc availability depends mainly on the fission-produced ⁹⁹Mo supply. This supply is seriously influenced during renewed emergency periods, such as the past ⁹⁹Mo production crisis or the current COVID-19 pandemic. Consequently, these interruptions have promoted the need for 99mTc production through alternative strategies capable of providing clinical-grade 99mTc with high purity. In the light of this context, this review illustrates diverse production routes that either have commercially been used or new strategies that offer potential solutions to promote a rapid production growth of 99mTc. These techniques have been selected, highlighted, and evaluated to imply their impact on developing 99mTc production. Furthermore, their advantages and limitations, current situation, and long-term perspective were also discussed. It appears that, on the one hand, careful attention needs to be devoted to enhancing the ⁹⁹Mo economy. It can be achieved by utilizing ⁹⁸Mo neutron activation in commercial nuclear power reactors and using accelerator-based ⁹⁹Mo production, especially the photonuclear transmutation strategy. On the other hand, more research efforts should be devoted to widening the utility of ⁹⁹Mo/99mTc generators, which incorporate nanomaterial-based sorbents and promote their development, validation, and full automization in the near future. These strategies are expected to play a vital role in providing sufficient clinical-grade 99mTc, resulting in a reasonable cost per patient dose.